A drug approved a week earlier for pancreatic cancer has shown activity against advanced lung tumors in an early-stage trial, opening a possible route for patients who currently have no targeted option.
The results, published in the New England Journal of Medicine and reported by the trial's lead center, come from the first-in-human phase 1/2 study of daraxonrasib, sold as Rasonque, in people with previously treated advanced RAS-mutant non-small cell lung cancer. Response rates ranged from 31 percent in the lowest dose group to 37 percent at the highest. In a post-hoc analysis of the dose range chosen for phase 3 testing, 38 patients showed a 42 percent objective response rate, a median duration of response of 11.5 months, median progression-free survival of 8.3 months, and median overall survival of 16 months.
